Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H101 combined with PD-1 antibody for advanced solid tumors
ChiCTR1800017971Phase 4Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Sep 2018
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Oncorine in Nonhematologic neoplasms, sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: objective response rate. Started Sep 2018; status: recruiting.
02
Drugs
Oncorine
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR1800017971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017971.